

CURRICULUM VITAE

DONNETTE STAAS, PH.D.

2005 Market Street, Suite 2100, Philadelphia, PA 19103 (W)
 Phone: 215-272-7524 (W) | E-mail: donnette.staas@jazzpharma.com

EDUCATION

M.S., Quality Assurance/Regulatory Affairs Temple University	Aug 2011
Ph.D., Chemistry Harvard University Thesis: "Carboxylic acid-mediated, Epoxide-initiated Cation-Olefin Cyclizations and 'A-Ring' Formation in Sterol Biosynthesis"	Jun 1998
A.M., Chemistry Harvard University	Jun 1994
A.B., Chemistry (<i>summa cum laude</i>) Columbia University	May 1992

TRAINING/CONTINUING EDUCATION

RISE – Merck Internal Leadership Program for Executive Directors and AVPs Designed to prepare leaders for upward succession, with focus on innovation, leadership, and the future of healthcare	Sep 2021- Apr 2022
Diverse Executive Coaching Circles	Sep 2021 – Mar 2022
McKinsey Black Executive Leadership Program	Sep-Dec 2020
Virus101x: Viruses & How to Beat Them: Cells, Immunity, Vaccines edX (IsraelX - Tel Aviv University) certificate course – final grade 99%	Aug 2020
Vital Signs: Understanding What the Body is Telling Us Coursera (University of Pennsylvania School of Nursing) certificate course – final grade 100%	May 2020
Clinical Vaccinology Course National Foundation for Infectious Diseases	Nov 15-17, 2019
Merck MRL Management Engagement Program Wharton Executive Education, The Wharton School, University of Pennsylvania	Sep 2016
Women's Leadership Program Simmons Executive Education, Simmons School of Management, Boston MA	Sep - Dec 2014

WORK EXPERIENCE – JAZZ PHARMACEUTICALS, INC. (JUNE 2023 – PRESENT)

Vice President, Regulatory Strategy, Global Regulatory Affairs & Drug Safety (June 2023 – Present)

Oversight of Global Regulatory Strategy for Neuroscience and Oncology Therapeutic Product Portfolio:

- Manage a group of 40+ Regulatory Affairs professionals with directed efforts in both domestic (US) and international markets to deliver on company strategic objectives across all phases of clinical development and product lifecycle management

WORK EXPERIENCE – MERCK, SHARP & DOHME, CORP, A SUBSIDIARY OF MERCK & CO., INC. (25 YEARS)

Global Regulatory Affairs & Clinical Safety (Mar 2012 – May 2023)

Consistently recognized as strong, collaborative, inclusive leader, strategic thinker, and mentor with deep scientific and regulatory expertise. Credited with creating and leading high-performing teams to drive results.

Associate Vice President (AVP), Oncology	Nov 2022 – May 2023
Associate Vice President (AVP), Vaccines	Nov 2020 – Nov 2022
Executive Director (ED), Antibacterial/Antifungal Medicines	Nov 2018 – Nov 2020

Key Accomplishments:

- **As therapeutic area lead, provided regulatory strategic direction and oversight for:**
 - Several global (e.g., US, Japan, EU) new drug and supplemental applications for *anti-infectives*, leading to approvals of new products/new indications
 - Investigational New Drug (IND) application filings for *vaccine and antibacterial assets*
 - Clinical development programs for *monoclonal antibody, vaccine and small molecule modalities* addressing a wide range of infectious diseases across the pediatric, adolescent, and adult populations
 - 10-12 programs comprising both marketed and development *antibacterial, antifungal, and antiviral* products
 - Approximately 15 programs comprising both marketed and development *vaccine* products, and several early and late-stage *oncology* assets, including combination therapy regimens
- **Maintained strong focus on people development and “building the bench”:**
 - Consistent focus on active development and coaching of 7-10 direct reports
 - Career mentorship of employees across multiple functional areas
- **Built strong collaborative and inclusive relationships with cross-functional peers:**
 - Close and consistent cross-functional collaboration with peer leaders (e.g., Clinical Research, Safety, Basic Research, Commercial) to devise solid strategies to enable target product profile and achieve successful regulatory agency interactions in support of desired clinical development approaches, including key labeling discussions
 - Provided strategic regulatory oversight for business interactions with external collaborators, including due diligence activities for external assets
 - Actively engaged in fostering a diverse and inclusive workplace through participation in cross-functional and cross-divisional initiatives and councils

Director/Senior Principal Scientist, Global Regulatory Lead	Jun 2015 – Oct 2018
Director/Principal Scientist, Regulatory Liaison	Mar 2012 – May 2015

Key Skills and Accomplishments:

- Provided regulatory strategic leadership for preparation, submission, regulatory review, and approval of original global marketing applications, including two original NDAs and one original BLA
- Experienced in leading teams through Regulatory Agency interactions (written, teleconference and face-to-face) in early-, mid- and late-stage *small molecule and biologic (monoclonal antibody)* drug development programs (*antiviral, anti-bacterial, and anti-fungal agents*):
 - Single point of contact between Merck and the FDA; recognized by FDA project managers for strong, positive, and timely collaboration
 - Agency Meeting experience:
 - US FDA: Type B meetings (End of Phase 2, pre-BLA, pre-NDA); Type C meetings (Clinical Development,

CMC); Mid- and Late-Cycle NDA/BLA Review meetings; Advisory Committee Meeting (gave introductory presentation at the ZINPLAVA™ ACM);

Ex-US: CHMP Scientific Advice; pre-NDS (Health Canada) and MAA pre-submission meetings; EU Scientific Advisory Group (SAG) meeting

- Experienced in filing Investigational New Drug (IND) Applications
- Experienced in regulatory strategy for pediatric drug development, including FDA initial Pediatric Study Plans and amendments, EMA Paediatric Investigation Plans and modifications.
- Recognized as a collaborative/inclusive leader in multiple settings, for peer mentorship and excellent oral and written communication skills:
 - Consistently recognized for deep understanding and clear articulation of key cross-functional issues (Clinical, CMC, Safety), and providing critical input to driving solutions

Chemistry, Modeling & Informatics (CM&I) Department (Nov 2009 – Feb 2012)

Senior Research Fellow, Central Chemistry Team Member

Nov 2009 – Feb 2012

Molecular modeling and chemo-informatics support for several pain/CNS therapeutic area targets and data mining projects; supervised associate chemist on rotation

Medicinal Chemistry Department (Feb 1998 – Oct 2009)

Senior Research Fellow

Jun 2006 – Oct 2009

Research Fellow

May 2002 – May 2006

Senior Research Chemist

Feb 1998 – Apr 2002

Key Programs:

- *Cardiovascular Disease*: Thrombin Inhibitors
- *Infectious Disease*: HIV-RNase H; HIV-Integrase
- *Pain/Migraine*: CGRP Receptor Antagonists

Co-author on several publications and co-inventor on several patents/patent applications across all three therapeutic areas (see below)

Managed direct reports (associate chemists and summer interns)

Medicinal Chemistry Safety Committee Chair

2002 – 2006

Oversight of laboratory compliance with safety and environmental regulations:

- Organized and conducted routine safety inspections
- Coordinated inspection follow-up with corrective actions
- Served as point of contact for departmental audits by MRL and Global Safety
- Assisted MRL safety contact with incident investigations

Communication of safety and environmental information to the department

ACADEMIC HONORS

Harvard University Graduate Prize Fellowship	1995 - 1997
NSF Predoctoral Fellowship	1992 - 1995
First Place Amgen Graduate Student Poster Award, Symposium at National Academy of Sciences	1995
Elected to Phi Beta Kappa, New York Delta Chapter	1992
Chemists' Club of New York Award	1992
Prize for excellence in the German Language, Columbia University	1992
NSF Incentives for Excellence Award	1991
NSF Summer Undergraduate Research Fellowship	1990
GSAS Minority Summer Research Fellowship, Columbia University	1990

ACADEMIC/TEACHING EXPERIENCE

- National Science Foundation Pre-doctoral Fellow, Harvard Graduate Prize Fellow** 1992-1997
Harvard University, Department of Chemistry
Advisor: Professor E.J. Corey
- Teaching Fellow** 1992-1996
Harvard University, Department of Chemistry
Instructor for Advanced Organic Synthesis laboratory course; section teaching assistant for introductory Organic Chemistry
- Teaching Assistant** 1991-1992
Columbia University, Department of Chemistry
Instructor for General Chemistry laboratory course
- National Science Foundation Undergraduate Summer Research Fellow** Summer 1990
Columbia University, Department of Chemistry
Advisor: Professor Ronald Breslow

OTHER EMPLOYMENT HISTORY

- Rohm and Haas Company, Agricultural Chemicals Division
Laboratory Assistant Summer 1992
Supervisor: Dr. Steven Shaber
- Rohm and Haas Company, Monomers Division
Laboratory Assistant Summer 1991
Supervisor: Dr. Sherry Jiang

PUBLICATIONS, PATENTS AND PRESENTATIONS**PUBLICATIONS**

1. Bell, S. Gallicchio, C. Stump, J. Bruno, H. Fan, L. Gantert, E. Hostetler, A. Kemmerer, M. McWherter, E. Moore, S. Mosser, M. Purcell, K. Riffel, C. Salvatore, S. Sanabria, D. Staas, R. White, Rebecca, M. Williams, C. Zartman, H. Selnick, Harold. (2013). [C-11]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor. *ACS Medicinal Chemistry Letters*. 4. 863-8 (2013).
2. M. Bell, C. A. Stump, S. N. Gallicchio, D. D. Staas, C. B. Zartman, E. L. Moore, N. Sain, M. Urban, J. G. Bruno, A. Calamari, A. L. Kemmerer, S. D. Mosser, C. Fandozzi, R. B. White, M. M. Zrada, H. G. Selnick, S. L. Graham, J. P. Vacca, C. A. Salvatore. MK-8825: A Potent and Selective CGRP Receptor Antagonist with Good Oral Activity in Rats. *Bioorg. Med. Chem. Lett.* 22, 3941-3945 (2012).
3. P.D. Williams, D.D. Staas, S. Venkatraman, H.M. Loughran, R.D. Ruzek, T.M. Booth, T.A. Lyle, J.S. Wai, J.P. Vacca, B.P. Feuston, L.T. Ecto, J.A. Flynn, D.J. DiStefano, D.J. Hazuda, C.D. Bahneck, A.L. Himmelberger, G. Dornadula, R.C. Hrin, K.A. Stillmock, M.V. Witmer, M.D. Miller, J.A. Grobler. Potent and Selective HIV-1 Ribonuclease H inhibitors based on a 1-Hydroxy-1,8-naphthyridin-2(1H)-one Scaffold. *Bioorg. Med. Chem. Lett.* 20, 6754-6757 (2010).
4. D. V. Paone, D. D. Staas. Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists for the Acute Treatment of Migraine: A Patent Review. *Expert Opin. Ther. Patents*, 19(12), 1675-1713 (2009).

5. J.S. Wai, B. Kim, T.E. Fisher, L. Zhuang, M.W. Embrey, P.D. Williams, D.D. Staas, C. Culberson, T.A. Lyle, J.P. Vacca, D.J. Hazuda, S.D. Young. Dihydroxypyridopyrazine-1,6-dione HIV-1 Integrase Inhibitors. *Bioorg. Med. Chem. Lett.*, 17, 5595-5599 (2007).
6. T.E. Fisher, B. Kim, D.D. Staas, T.A. Lyle, S.D. Young, J.P. Vacca, M.M. Zrada, D.J. Hazuda, P.J. Felock, W.A. Schleif, L.J. Gabryelski, M.R. Anari, C.J. Kochansky, J.S. Wai. 8-Hydroxy-3,4-dihydropyrrolo[1,2-a]pyrazine-1(2H)-one HIV-1 integrase inhibitors. *Bioorg. Med. Chem. Lett.*, 17, 6511-6515. (2007)
7. D.D. Staas, K.L. Savage, V.L. Sherman, H.L. Shimp, T.A. Lyle, L.O. Tran, C.M. Wiscount, D.R. McMasters, P.E.J. Sanderson, P.D. Williams, B.J. Lucas, Jr., J.A. Krueger, S.D. Lewis, R.B. White, S. Yu, B.K. Wong, C.J. Kochansky, M.R. Anari, Y. Yan, J.P. Vacca. Discovery of Potent, Selective 4-Fluoroproline-Based Thrombin Inhibitors with Improved Metabolic Stability. *Bioorg. Med. Chem.*, 14, 6900-6916 (2006).
8. D. D. Staas, K. L. Savage, C. F. Homnick, N. N. Tsou, R. G. Ball. Asymmetric Synthesis of α,α -Difluoro- β -amino Acid Derivatives from Enantiomerically Pure N-tert-Butylsulfonimines. *J. Org. Chem.*, 67(23), 8276-8279 (2002).
9. Staas, Donnette Daley. Carboxylic acid-mediated, Epoxide-initiated Cation-Olefin Cyclizations and "A-Ring" Formation in Sterol Biosynthesis. Harvard University, Cambridge, MA, USA. Ph.D. Dissertation. *Diss. Abstr. Int.*, B 59(5), 2210 (1998).
10. E. J. Corey, D. C. Daley.[†] Demonstration of a Common Concerted Mechanistic Pathway for the Acid-catalyzed Cyclization of 5,6-Unsaturated Oxiranes in Chemical and Enzymatic Systems. *J. Amer. Chem. Soc.*, 120, 3526 (1998).
11. E. J. Corey, D. C. Daley,[†] H. Cheng. A Structural Analog of the Protosterol Cation is Not a Strong Inhibitor of Sterol Biosynthesis. *Tet. Lett.*, 37, 3287 (1996).
12. E. J. Corey, T.-P. Loh, S. AchyuthaRao, D. C. Daley,[†] S. J. Sarshar. Stereocontrolled Total Synthesis of (+) and (-)-Epibatidine. *J. Org. Chem.*, 48, 5600 (1993).

PATENTS

1. US Patent 9,833,448, December 5, 2017
M. Bell, M. E. Fraley, S. N. Gallicchio, A. Ginnetti, H. J. Mitchell, D. V. Paone, D. D. Staas, C. Wang, C. B. Zartman
"Piperidinone carboxamide azaindane CGRP receptor antagonists"
2. US Patent 9,499,545, November 22, 2016
M. Bell, M. E. Fraley, S. N. Gallicchio, A. Ginnetti, H. J. Mitchell, D. V. Paone, D. D. Staas, C. Wang, C. B. Zartman
"Piperidinone carboxamide azaindane CGRP receptor antagonists"
3. US Patent 9,499,541, November 22, 2016
M. Bell, M. E. Fraley, S. N. Gallicchio, A. Ginnetti, H. J. Mitchell, D. V. Paone, D. D. Staas, C. Wang, C. B. Zartman, H. E. Stevenson
"Piperidinone carboxamide azaindane CGRP receptor antagonists"

4. US Patent 8,912,210, December 16, 2014
M. Bell, M. E. Fraley, S. N. Gallicchio, A. Ginnetti, H. J. Mitchell, D. V. Paone, D. D. Staas, C. Wang, C. B. Zartman
“Piperidinone carboxamide azaindane CGRP receptor antagonists”
5. US Patent 8,883,807, November 11, 2014
M. Bell, M. E. Fraley, S. N. Gallicchio, A. Ginnetti, H. J. Mitchell, D. V. Paone, D. D. Staas, C. Wang, C. B. Zartman, H. E. Stevenson
“Piperidinone carboxamide azaindane CGRP receptor antagonists”
6. US Patent 8,765,759, July 1, 2014
H. G. Selnick, I. M. Bell, M. McWherter, D. D. Staas, S. J. Stachel, T. Steele, C. Stump, M. R. Wood, C. Wang, C. B. Zartman
“Monocyclic CGRP receptor antagonists”
7. US Patent 8,754,096, June 17, 2014
M. Bell, M. E. Fraley, S. N. Gallicchio, A. Ginnetti, H. J. Mitchell, D. V. Paone, D. D. Staas, H. E. Stevenson, C. Wang, C. B. Zartman
“Piperidinone carboxamide azaindane CGRP receptor antagonists”
8. US Patent 8,685,965, April 1, 2014
D. D. Staas, I. M. Bell, H. G. Selnick
“CGRP receptor antagonists”
9. US Patent 7,820,680, October 26, 2010
P. D. Williams, J. S. Wai, M. W. Embrey, D. D. Staas, L. Zhuang
“HIV integrase inhibitors”
10. US Patent 7,538,112, May 26, 2009
J. S. Wai, J. P. Vacca, L. Zhuang, B. Kim, T. A. Lyle, C. M. Wiscount, M. S. Egbertson, L. Neilson, M. Embrey, T. E. Fisher, D. D. Staas
“HIV integrase inhibitors”
11. US Patent 7,435,735, October 14, 2008
J. S. Wai, T. E. Fisher, L. Zhuang, D. D. Staas, T. A. Lyle, B. Kim, M. W. Embrey, C. M. Wiscount, L. O. Tran, M. Egbertson, K. L. Savage
“Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors”
12. US Patent 7,144,899, December 5, 2006
H. G. Selnick, M. Young, P. G. Nantermet, J. C. Barrow, P. D. Williams, T. A. Lyle, D. D. Staas, K. J. Stauffer, P. E. Sanderson
“Thrombin inhibitors”
13. US Patent 6,610,692, August 26, 2003
P. E. Sanderson, B. D. Dorsey, T. A. Lyle, M. G. Stanton, D. Staas, A. M. Naylor-Olsen, C. Coburn, M. M. Morrisette
“Thrombin inhibitors”

14. US Patent 6,528,503, March 4, 2003
P. D. Williams, T. A. Lyle, M. M. Morrisette, L. O. Tran, D. D. Staas
"Thrombin inhibitors"
15. US Patent 6,515,011, February 4, 2003
H. G. Selnick, J. C. Barrow, P. G. Nantermet, P. D. Williams, K. J. Stauffer, P. E. Sanderson, K. E. Rittle, M. M. Morrisette, C. M. Wiscount, L. O. Tran, T. A. Lyle, D. D. Staas
"Thrombin inhibitors"
16. US Patent 6,387,911, May 14, 2002
C. S. Burgey, R. C. Isaacs, B. D. Dorsey, K. A. Robinson, D. Staas, P. E. Sanderson, J. Barrow
"Pyrazinone Thrombin Inhibitors"

PATENT APPLICATIONS

1. US 20180092900
Ian M. Bell, Mark E. Fraley, Steven N. Gallicchio, Anthony Ginetti, Helen J. Mitchell, Daniel V. Paone, Donnette D. Staas, Cheng Wang, C. Blair Zartman
"Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists"
2. WO 20170027925
Ian M. Bell, Mark E. Fraley, Steven N. Gallicchio, Anthony Ginetti, Helen J. Mitchell, Daniel V. Paone, Donnette D. Staas, Cheng Wang, C. Blair Zartman
"Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists"
3. US 20170027925
Ian M. Bell, Mark E. Fraley, Steven N. Gallicchio, Anthony Ginetti, Helen J. Mitchell, Daniel V. Paone, Donnette D. Staas, Cheng Wang, C. Blair Zartman, Heather E. Stevenson
"Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists"
4. US 20150031716
Ian M. Bell, Mark E. Fraley, Steven N. Gallicchio, Anthony Ginetti, Helen J. Mitchell, Daniel V. Paone, Donnette D. Staas, Cheng Wang, C. Blair Zartman, Heather E. Stevenson
"Piperidinone Carboxamide Indane CGRP Receptor Antagonists"
5. US 20150005330
Ian M. Bell, Mark E. Fraley, Steven N. Gallicchio, Anthony Ginetti, Helen J. Mitchell, Daniel V. Paone, Donnette D. Staas, Cheng Wang, C. Blair Zartman
"Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists"
6. US 20130231358
Ian M. Bell, Mark E. Fraley, Steven N. Gallicchio, Anthony Ginetti, Helen J. Mitchell, Daniel V. Paone, Donnette D. Staas, Cheng Wang, C. Blair Zartman, Heather E. Stevenson
"Piperidinone Carboxamide Indane CGRP Receptor Antagonists"
7. WO 20120122900
Ian M. Bell, Mark E. Fraley, Steven N. Gallicchio, Anthony Ginetti, Helen J. Mitchell, Daniel V. Paone, Donnette D. Staas, Cheng Wang, C. Blair Zartman

"Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists"

8. US 20120122899
Ian M. Bell, Mark E. Fraley, Steven N. Gallicchio, Anthony Ginetti, Helen J. Mitchell, Daniel V. Paone, Donnette D. Staas, Cheng Wang, C. Blair Zartman
"Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists"
9. US 20110245240
Donnette D. Staas, Ian M. Bell, Michael R. Wood
"CGRP Receptor Antagonists"
10. US 20110224201
Donnette D. Staas, Ian M. Bell, Harold G. Selnick
"CGRP Receptor Antagonists"
11. US 20110021516
Harold G. Selnick, Ian M. Bell, Melody McWherter, Donnette D. Staas, Shawn J. Stachel, Thomas Steele, Craig Stump, Michael R. Wood, C. Blair Zartman
"Monocyclic CGRP Receptor Antagonists"
12. WO 2010042356
Staas, Donnette D.; Bell, Ian M.; Wood, Michael R.
"Preparation of Benzocyclicacetamide Derivatives for use as CGRP Receptor Antagonists."
13. WO 2010039673
Staas, Donnette D.; Bell, Ian M.; Selnick, Harold G.
"CGRP Receptor Antagonists."
14. WO 2009120652
Selnick, Harold G.; Bell, Ian M.; McWherter, Melody; Staas, Donnette D.; Stachel, Shawn J.; Steele, Thomas; Stump, Craig; Wood, Michael R.; Zartman, C. Blair.
"Preparation of Pyrrolopyridine containing Spiro Compounds as CGRP Receptor Antagonists."
15. US 20080287394
John S. Wai, Joseph P. Vacca, Linghang Zhuang, Boyoung Kim, Terry A. Lyle, Catherine M. Wiscount, Melissa S. Egbertson, Lou Anne Neilson, Mark Embrey, Thorsten E. Fisher, Donnette D. Staas
"HIV Integrase Inhibitors"
16. WO 2008010964
Williams, Peter D.; Venkatraman, Shankar; Langford, H. Marie; Kim, Boyoung; Booth, Theresa M.; Grobler, Jay A.; Staas, Donnette; Ruzek, Rowena D.; Embrey, Mark W.; Wiscount, Catherine M.; Lyle, Terry A.
"Preparation of 1-hydroxynaphthyridin-2(1H)-one derivatives as anti-HIV agents."
17. WO 2005110415
Wai, John S.; Vacca, Joseph P.; Zhuang, Linghang; Kim, Boyoung; Lyle, Terry A.; Wiscount, Catherine M.; Egbertson, Melissa S.; Neilson, Lou Anne; Embrey, Mark; Fisher, Thorsten E.; Staas, Donnette D.
"Pyrzainopyrrolopyridazines as HIV integrase inhibitors, their preparation, pharmaceutical compositions, and use to prevent or treat HIV infection."

18. WO 2005092099
Williams, Peter D.; Wai, John S.; Embrey, Mark W.; Staas, Donnette D.; Zhuang, Linghang; Langford, H. Marie.
"Preparation of 2H-pyrazino[1,2-c]pyrimidines as HIV integrase inhibitors."
19. WO 2004032834
Staas, Donnette D.; Lyle, Terry A.; Williams, Peter D.; Sanderson, Philip E. J.
"Preparation of amino acid benzylamide derivatives as thrombin inhibitors."
20. US 20040073025
Harold G Selnick, Mary Beth Young, Philippe G Nantermet, James C Barrow, Peter D Williams, Terry A Lyle, Donnette D Staas, Kenneth J Stauffer, Philip E Sanderson
"Thrombin Inhibitors"
21. US 20030013700
Williams, Peter D.; Lyle, Terry A.; Morrissette, Matthew M.; Tran, Lekhanh O.; Staas, Donnette D.
"Preparation of 1-(hydroxyalkanoyl)azetidine-2-carboxamides as thrombin inhibitors."
22. WO 2002057225
Selnick, Harold G.; Rittle, Kenneth E.; Barrow, James C.; Nantermet, Philippe G.; Staas, Donnette; Morrissette, Matthew M.
"Preparation of pyrazinylaminomethylbenzylacetamide derivatives as thrombin inhibitors"
23. WO 2002050056
Selnick, Harold G.; Barrow, James C.; Nantermet, Philippe G.; Williams, Peter D.; Stauffer, Kenneth J.; Sanderson, Philip E.; Rittle, Kenneth E.; Morrissette, Matthew M.; Wiscount, Catherine M.; Tran, Lekhanh O.; Lyle, Terry A.; Staas, Donnette D.
"Preparation of proline benzylamide derivatives as thrombin inhibitors"
24. WO 2002022584
Isaacs, Richard C.; Williams, Peter D.; Lyle, Terry A.; Staas, Donnette D.; Savage, Kelly L.
"Preparation of substituted heterocyclic aryl-alkyl-aryl compounds as thrombin inhibitors"
25. US 20020119992
Harold G. Selnick, James C. Barrow, Philippe G. Nantermet, Peter D. Williams, Kenneth J. Stauffer, Philip E. Sanderson, Kenneth E. Rittle, Matthew M. Morrissette, Catherine M. Wiscount, Lekhanh O. Tran, Terry A. Lyle, Donnette D. Staas
"Thrombin Inhibitors"

PRESENTATIONS AND POSTERS

1. "Discovery of a novel class of orally active CGRP receptor antagonists for the treatment of migraine."
Ian M. Bell, Lianyun Zhao, Edward J. Brnardic, Joseph G. Bruno, Brendan M. Crowley, Andrew Danziger, Steven N. Gallicchio, Matthew J. Mitcheltree, Eric L. Moore, Scott D. Mosser, Diem N. Nguyen, Donnette D. Staas, Hua Su, Cheng Wang, Rebecca B. White, C. Blair Zartman, Christopher A. Salvatore, Christopher S. Burgey, and Mark E. Fraley. ACS National Meeting, Boston, MA, United States, August 19-23, **2018**

2. "Discovery of [11C]MK-4232 as a promising PET tracer for the calcitonin gene-related peptide receptor." Gallicchio, Steven N.*; Bell, Ian M.; Graham, Sam L.; Hostetler, Eric; Kane, Stefanie A.; Kim, June; Quigley, Amy G.; Salvatore, Chris A.; Selnick, Harold G.; Staas, Donnette D.; Stump, Craig A.; Wood, Michael R.; Zartman, C. B. Abstracts of Papers, 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, **2010**
3. "Discovery of [11C]MK-4232: The first CGRP-R PET Tracer." Selnick, Harold G.*; Bell, Ian M.; Gallicchio, Steven; Kim, June; McWherter, Melody; Stump, Craig; Wood, Michael; Quigley, Amy; Zartman, C. Blair; Staas, Donnette; Hostetler, Eric; Sanabria, Sandra; Sur, Cyrille; Williams, David; Zeng, Zhizhen; Kane, Stefanie; Salvatore, Christopher; White, Rebecca; Moore, Eric; Graham, Samuel. Abstracts of Papers, 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, **2010**
4. "CGRP Receptor Antagonists for the Acute Treatment of Migraine." D. D. Staas.* Oral Presentation given at CHI Discovery on Target Conference: GPCR-Based Discovery. Boston, MA, November 2-3, **2009**.
5. CSF levels and binding pattern of novel CGRP receptor antagonists in rhesus monkey and human central nervous system: toward the development of a pet tracer." Sur, C.,* Hargreaves, R.J., Bell, I.M., Dancho, M., Graham, S.L., Hostetler, E.D., Kane, S.A., Kim, J.J., Michener, M.S., Miller, P.J., O'malley, S.S., Salvatore, C.A., Selnick, H.G., Staas, D.D., Stump, C.A., Gallicchio, S.N., Williams, D.L., Wood, M.J., Zeng, Z., Cook, J.J. American Headache Society 14th International Headache Congress, Philadelphia, Pennsylvania, September 10-13, **2009**.
6. Inhibitors of the RNase H Activity of Reverse Transcriptase as an Approach to New HIV-1 Antiretroviral Agents" P. D. Williams,* D. Staas, S. Venkatraman, J. Wai, S. Munshi, S. Prasad, J Grobler, M. Miller, and D Hazuda. 16th Conference on Retroviruses and Opportunistic Infections (CROI), Montreal, Canada, February 8-11, **2009**.
7. "Tricyclic 10-hydroxy-7, 8-dihydropyrazinopyrrolopyrazine-1, 9-diones as potent, orally bioavailable HIV-1 integrase strand transfer inhibitors." Wiscount, Catherine M.*; Tran, Lekhanh O.; Embrey, Mark W.; Fisher, Thorsten E.; Sherman, Vanessa; Staas, Donnette D.; Williams, Peter; Wai, John; Lyle, Terry A.; Vacca, Joseph; Felock, Peter J.; Witmer, Marc V.; Gabryelski, Lori; Miller, Michael D.; Hazuda, Daria J.; Ecto, Linda; Schleif, W. A.; Kochansky, Christopher J.; Anari, M. Reza. Abstracts of Papers, 235th ACS National Meeting, New Orleans, LA, United States, April 6-10, **2008**.
8. "Understanding Sterol Biosynthesis." E. J. Corey, D. C. Daley.*† Poster Presentation, Leadership Alliance Symposium at the National Academy of Sciences, Washington, DC **1995**.

SOCIETY MEMBERSHIPS

Infectious Diseases Society of America	2017 - Present
Drug Information Association	2012 - Present
American Chemical Society	1991 - Present

LANGUAGES

English – native language

Spanish – read/write with good proficiency; speak with basic competence

German – read/write with basic competence

[†]*Maiden name*